Open source and sustainability: the role of universities.

One important goal in sustainability is making technologies available to the maximum possible number of individuals, and especially to those living in less developed areas (Goal 9 of SDG). However, the diffusion of technical knowledge is hindered by a number of factors, among which the Intellectual Property Rights (IPR) system plays a primary role. While opinions about the real effect of IPRs in stimulating and disseminating innovation differ, there is a growing number of authors arguing that a different approach may be more effective in promoting global development. The success of the Open Source (OS) model in the field of software has led analysts to speculate whether this paradigm can be extended to other fields. Key to this model are both free access to knowledge and the right to use other people's results. Abstract After reviewing the main features of the OS model, we explore different areas where it can be profitably applied, such as hardware design and production; we finally discuss how academical institutions can (and should) help diffusing the OS philosophy and practice. Widespread use of OS software, fostering of research projects aimed to use and develop OS software and hardware, the use of open education tools, and a strong commitment to open access publishing are some of the discussed examples.Comment: first draft of a contribution for Symposium On Sustainability In University Campuses (SSUC- 2018) Florence, Italy, December 201

Autoantibodies to Interferons in Infectious Diseases

Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infections with several agents. For instance, anti-type I interferon autoantibodies are implicated in Coronavirus Disease 19 (COVID-19) pathogenesis and found preferentially in patients with critical disease. However, autoantibodies were also described in the serum of patients with viral, bacterial, and fungal infections not associated with COVID-19. In this review, we provide an overview of anti-cytokine autoantibodies identified to date and their clinical associations; we also discuss whether they can act as enemies or friends, i.e., are capable of acting in a beneficial or harmful way, and if they may be linked to gender or immunosenescence. Understanding the mechanisms underlying the production of autoantibodies could improve the approach to treating some infections, focusing not only on pathogens, but also on the possibility of a low degree of autoimmunity in patients